Serum Thyroglobulin as a Risk Factor for Thyroid Carcinoma

Hrafnkelsson, Hrafn

doi:10.1080/02841860050215963

Cited by 25 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another interesting finding in our cohort was that the risk of thyroid cancer was approximately four times higher in those with serum levels of TG > 60 ng/mL compared with those with TG < 15 ng/mL. This association persisted after adjustment for presence of diffuse goiter or ultrasound-detected nodules at the first screening examination and is consistent with a previous report suggesting that serum TG, in addition to its established link with iodine deficiency, may be an early marker of thyroid cancer risk (Hrafnkelsson et al 2000). …”

Section: Discussionsupporting

confidence: 90%

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident

Brenner

Тronko

Hatch

et al. 2011

Environ Health Perspect

189

153

View full text Add to dashboard Cite

Background: Current knowledge about Chornobyl-related thyroid cancer risks comes from ecological studies based on grouped doses, case–control studies, and studies of prevalent cancers.Objective: To address this limitation, we evaluated the dose–response relationship for incident thyroid cancers using measurement-based individual iodine-131 (I-131) thyroid dose estimates in a prospective analytic cohort study.Methods: The cohort consists of individuals < 18 years of age on 26 April 1986 who resided in three contaminated oblasts (states) of Ukraine and underwent up to four thyroid screening examinations between 1998 and 2007 (n = 12,514). Thyroid doses of I-131 were estimated based on individual radioactivity measurements taken within 2 months after the accident, environmental transport models, and interview data. Excess radiation risks were estimated using Poisson regression models.Results: Sixty-five incident thyroid cancers were diagnosed during the second through fourth screenings and 73,004 person-years (PY) of observation. The dose–response relationship was consistent with linearity on relative and absolute scales, although the excess relative risk (ERR) model described data better than did the excess absolute risk (EAR) model. The ERR per gray was 1.91 [95% confidence interval (CI), 0.43–6.34], and the EAR per 104 PY/Gy was 2.21 (95% CI, 0.04–5.78). The ERR per gray varied significantly by oblast of residence but not by time since exposure, use of iodine prophylaxis, iodine status, sex, age, or tumor size.Conclusions: I-131–related thyroid cancer risks persisted for two decades after exposure, with no evidence of decrease during the observation period. The radiation risks, although smaller, are compatible with those of retrospective and ecological post-Chornobyl studies.

show abstract

Section: Discussionsupporting

confidence: 90%

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident

Brenner

Тronko

Hatch

et al. 2011

Environ Health Perspect

189

153

View full text Add to dashboard Cite

show abstract

“…Pellegriti et al reported that circulating TSH receptor-stimulating antibodies (TSHR-Abs) were present in all patients with Graves’ disease [ 18 ], implying an association between TSHR-Abs and elevated levels of thyroid hormones. TSHR-Abs are known to stimulate the same intracellular signal pathways as TSH, which has mitogenic and antiapoptotic effects on thyroid follicular cells and thus may play a role in thyroid cancer initiation [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case–control study

et al. 2014

View full text Add to dashboard Cite

BackgroundA remarkable increase in the number of thyroid cancer cases has been reported in recent years; however, the markers to predict high-risk groups have not been fully established.MethodsWe conducted a case–control study (257 cases and 257 controls) that was nested in the Cancer Screenee Cohort Study between August 2002 and December 2010; the mean follow-up time for this study was 3.1 ± 2.2 years. The levels of total triiodothyronine (TT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), thyroglobulin (Tg), anti-thyroperoxidase antibody (TPOAb), and anti-thyroglobulin antibody (TgAb) were measured using samples with pre-diagnostic status. Logistic regression models were used to examine the association between thyroid function/autoimmunity and thyroid cancer risk.ResultsWhen the markers were categorized by the tertile distributions of the control group, the highest tertile of FT4 (OR = 1.73, 95% CI = 1.11 - 2.69) and the middle tertile of TSH (OR = 1.77, 95% CI = 1.14 - 2.74) were associated with an increased risk of thyroid cancer by multivariate analyses. In addition, an elevated risk for thyroid cancer was found in subjects with TPOAb levels above 30 IU/mL (OR = 8.47, 95% CI = 5.39 - 13.33 for 30–60 IU/mL and OR = 4.48, 95% CI = 2.59 - 7.76 for ≥60 IU/mL). Stratified analyses indicated that some of these associations differed by sex, BMI, smoking status, and the duration of follow-up.ConclusionsThis study demonstrated that the levels of biomarkers of thyroid function/autoimmunity, particularly the presence of TPOAb, might be used as diagnostic markers for predicting thyroid cancer risk. Our findings suggest that careful monitoring of thyroid biomarkers may be helpful for identifying Korean populations at high-risk for thyroid cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-873) contains supplementary material, which is available to authorized users.

show abstract

“…However, most of the TSH data in these studies were obtained from patients presenting with thyroid nodules. Only one study included a healthy control group and reported that no differences were found between thyroid cancer and healthy control groups in TSH values [27]. Kim et al [26] compared TSH levels obtained from euthyroid patients with differentiated thyroid cancer to TSH levels from controls in the general population.…”

Section: Discussionmentioning

confidence: 99%

Co-Existence of Thyroid Nodule and Thyroid Cancer in Children and Adolescents with Hashimoto Thyroiditis: A Single-Center Study

Keskin¹,

Savaş‐Erdeve²,

Aycan³

2016

Horm Res Paediatr

View full text Add to dashboard Cite

Background: Currently, there is an inadequate number of studies on nodule and malignancy development in children and adolescents with Hashimoto thyroiditis (HT). Material and Methods: Patients who were diagnosed with HT between 2004 and 2013 were included in the study. The HT diagnosis was made with a heterogeneous appearance on thyroid ultrasonography and the elevation of antithyroid peroxidase and/or anti-thyroglobulin antibodies. Fine-needle aspiration biopsy (FNAB) was performed in cases with a nodule size >1 cm or who had ultrasonography findings indicating malignancy. Results: A total of 39 (13%) thyroid nodules were detected in 300 patients with a diagnosis of HT. Papillary thyroid carcinoma (PTC) was diagnosed in 2 of the 12 cases in whom FNAB was performed. The thyroid nodule was detected at the same time as HT in the 2 cases with malignancy. The PTC diagnosis was made 2 years after the HT diagnosis in the first case and 3 years later in the second case. The largest diameter of the thyroid nodule was 5 mm in both cases. Conclusion: The thyroid nodule rate on an HT background was found to be 13%, and the thyroid malignancy rate was 0.67% in our study.

show abstract

Serum Thyroglobulin as a Risk Factor for Thyroid Carcinoma

Cited by 25 publications

References 9 publications

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident

Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case–control study

Co-Existence of Thyroid Nodule and Thyroid Cancer in Children and Adolescents with Hashimoto Thyroiditis: A Single-Center Study

Contact Info

Product

Resources

About